MICROtransplant to refractory acute myeloid leukemia in Egyptian population
Purpose of review
The purpose of this review is to outline Egyptian experience of nonengraftment haploidentical cellular therapy [microtransplantation (MST)] for patients with refractory acute myeloid leukemia.
Recent findings
The use of granulocyte colony-stimulating factor primed halo-identical MST appears to be a biologically active therapy in patients with refractory acute myeloid leukemia (AML), especially in patients received less than four previous chemotherapy lines, fludarabine-free previous chemotherapy, response naïve and young age patients.
Summary
Refractory AML is still challenging. MST is promising, however the optimum conditioning, stem-cell dose, matching degree are factors should be optimized.
Source: Current Opinion in Hematology - Category: Hematology Tags: HEMATOPOIETIC STEM CELL TRANSPLANTATION: Edited by David Rizzieri Source Type: research
More News: Acute Leukemia | Acute Myeloid Leukemia | Chemotherapy | Egypt Health | Hematology | Leukemia | Stem Cell Therapy | Stem Cells | Transplants